ABSTRACT
Objective Diabetes mellitus significantly increases the risk of severe respiratory virus disease like influenza and COVID-19. Early evidence suggests that this susceptibility to respiratory viral disease is driven by glycaemic variability, rather than average blood glucose levels. In healthy individuals, blood glucose levels remain relatively stable throughout the day. However, in individuals living with diabetes, blood glucose spikes are more frequent and higher in magnitude. Continuous glucose monitoring (CGM) provides a unique opportunity to detect these hyper and hypoglycaemic events, even in the presence of an in range HbA1c.
Research design and methods Here, we use blood samples and CGM data obtained from people living with Type 1 diabetes (T1D) to determine the effects of glycaemic variability on the T-cell response to influenza virus. Low glycaemic variability was defined as a coefficient of variation (CV) <33% (n = 13) whilst high glycaemic variability was defined as a CV >33% (n = 19).
Results We show that high glycaemic variability in participants living with T1D is associated with a reduced proportion of CD8+CD107α-IFNγ-MIP1β-TNF+ T-cells in response to stimulation with influenza virus and an influenza peptide pool. High glycaemic variability in this patient population is primarily driven by hypoglycaemic events and was also associated with an increase in the proportion of naïve CD8+ T cells and a decrease in terminally differentiated CD8+ T cells (TEMRA).
Conclusions Together, this study provides the first evidence that glycaemic variability affects the T- cell response to respiratory viruses. These data suggest that monitoring glycaemic variability may have important implications in understanding the antiviral immune response in people with diabetes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to thank all individuals who participated in this study. This project was supported by the National Health and Medical Research Council (NHMRC; APP1159959). KRS is supported by NHMRC investigator grant 2007919. CES was supported by the ARC-DECRA Fellowship (#DE220100185) and the University of Melbourne Establishment Grant. KK was supported by the NHMRC Leadership Investigator Grant (#1173871). EJG is supported by an Australian Research Council (ARC) DECRA Fellowship (DE210101479). SG is supported by an NHMRC Senior Research Fellowship (#1159272). L.C.R. is a recipient of a NHMRC EL1 Fellowship (#2026357).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by Mater Research Ethics Committee (HREC/MML/55151 V2) and the University of Queensland Ethics Committee (2019/HE002522).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
